Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options.
GLP-1 agonists
liraglutide
obesity
residual cardiovascular risk
semaglutide
visceral adipose tissue
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
03
2023
accepted:
13
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Obesity is a heterogeneous disease that affects almost one-third of the global population. A clear association has been established between obesity and cardiovascular disease (CVD). However, CVD risk is known to be related more to the local distribution of fat than to total body fat. Visceral adipose tissue (VAT) in particular has a high impact on CVD risk. This manuscript reviews the role of VAT in residual CV risk and the available therapeutic strategies for decreasing residual CV risk related to VAT accumulation. Among the many pathways involved in residual CV risk, obesity and particularly VAT accumulation play a major role by generating low-grade systemic inflammation, which in turn has a high prognostic impact on all-cause mortality and myocardial infarction. In recent years, many therapeutic approaches have been developed to reduce body weight. Orlistat was shown to reduce both weight and VAT but has low tolerability and many drug-drug interactions. Naltrexone-bupropion combination lowers body weight but has frequent side effects and is contraindicated in patients with uncontrolled hypertension. Liraglutide and semaglutide, glucagon-like peptide 1 (GLP-1) agonists, are the latest drugs approved for the treatment of obesity, and both have been shown to induce significant body weight loss. Liraglutide, semaglutide and other GLP-1 agonists also showed a positive effect on CV outcomes in diabetic patients. In addition, liraglutide showed to specifically reduce VAT and inflammatory biomarkers in obese patients without diabetes. GLP-1 agonists are promising compounds to limit inflammation in human visceral adipocytes.
Identifiants
pubmed: 37576108
doi: 10.3389/fcvm.2023.1187735
pmc: PMC10421666
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1187735Informations de copyright
© 2023 Cesaro, De Michele, Fimiani, Acerbo, Scherillo, Signore, Rotolo, Scialla, Raucci, Panico, Gragnano, Moscarella, Scudiero, Mennitti and Calabrò.
Déclaration de conflit d'intérêts
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AM declared a past co-authorship with the authors AC and PC to the handling editor.
Références
Pharmacotherapy. 2000 Mar;20(3):270-9
pubmed: 10730683
Compr Physiol. 2018 Jun 18;8(3):1031-1063
pubmed: 29978896
Cell Metab. 2013 Jun 4;17(6):851-859
pubmed: 23747244
Metabolism. 1992 Nov;41(11):1242-8
pubmed: 1435298
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Hypertension. 2010 Nov;56(5):901-6
pubmed: 20837881
Int J Obes Relat Metab Disord. 2001 Jul;25(7):1068-70
pubmed: 11443508
J Am Heart Assoc. 2018 May 8;7(10):
pubmed: 29739793
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Ther Adv Chronic Dis. 2011 Sep;2(5):307-23
pubmed: 23251757
Circulation. 2012 Sep 4;126(10):1301-13
pubmed: 22949540
Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605
pubmed: 34358471
BMJ. 1998 Jul 18;317(7152):167-71
pubmed: 9665894
Indian J Med Res. 2019 May;149(5):571-573
pubmed: 31417024
Br J Radiol. 2018 Sep;91(1089):20170959
pubmed: 29722568
Hypertension. 2002 Jan;39(1):105-10
pubmed: 11799087
Sci Rep. 2017 Jul 10;7(1):5012
pubmed: 28694524
Vasc Health Risk Manag. 2016 May 06;12:171-83
pubmed: 27226718
Metabolism. 2019 Mar;92:6-10
pubmed: 30253139
Nutrients. 2013 May 10;5(5):1544-60
pubmed: 23666091
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Intern Emerg Med. 2011 Oct;6 Suppl 1:45-51
pubmed: 22009612
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Nature. 2014 Jun 5;510(7503):84-91
pubmed: 24899308
Lancet. 1998 Mar 7;351(9104):737-42
pubmed: 9504534
Stroke. 2007 Sep;38(9):2422-9
pubmed: 17673711
Am J Epidemiol. 2022 Jun 27;191(7):1235-1247
pubmed: 35247051
Cardiovasc Diabetol. 2018 Oct 10;17(1):134
pubmed: 30305178
Arch Med Sci. 2020 Sep 10;17(4):940-953
pubmed: 34336024
Mol Metab. 2015 Aug 12;4(11):779-94
pubmed: 26629403
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Annu Rev Physiol. 2008;70:537-56
pubmed: 17937601
Pharmacol Ther. 2020 Jan;205:107417
pubmed: 31629010
Nutr Metab (Lond). 2004 Nov 05;1(1):12
pubmed: 15530168
TH Open. 2017 Dec 15;1(2):e146-e154
pubmed: 31249920
EClinicalMedicine. 2023 Mar 20;58:101882
pubmed: 36992862
Am J Epidemiol. 1996 Feb 1;143(3):228-39
pubmed: 8561156
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
BMC Med. 2022 Dec 27;20(1):494
pubmed: 36575472
Diabetes Care. 2014;37(3):821-9
pubmed: 24186879
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Curr Hypertens Rep. 2001 Apr;3(2):152-6
pubmed: 11276398
Front Endocrinol (Lausanne). 2022 Aug 26;13:951570
pubmed: 36093105
Obesity (Silver Spring). 2013 Jan;21(1):E41-50
pubmed: 23404678
Diabetes Care. 2011 May;34 Suppl 2:S371-9
pubmed: 21525485
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
J Intern Med. 2016 Aug;280(2):209-20
pubmed: 26864622
Diabetes Obes Metab. 2018 Sep;20(9):2059-2063
pubmed: 29740935
Clin Pharmacol Ther. 1991 Oct;50(4):363-71
pubmed: 1914371
Eur J Clin Invest. 1985 Oct;15(5):267-71
pubmed: 3935457
Ann Nutr Metab. 2001;45(2):67-71
pubmed: 11359031
J Clin Endocrinol Metab. 1992 Jul;75(1):15-20
pubmed: 1320047
JAMA Pediatr. 2020 Jun 1;174(6):609-617
pubmed: 32202626
Diabetes Care. 2012 Nov;35(11):2359-64
pubmed: 22829522
Nat Rev Cardiol. 2019 Feb;16(2):83-99
pubmed: 30287946
Metabolism. 2015 Jan;64(1):24-34
pubmed: 25199978
Int J Obes (Lond). 2008 Sep;32(9):1431-7
pubmed: 18607383
Circulation. 1994 Aug;90(2):775-8
pubmed: 8044947
Int J Obes Relat Metab Disord. 2001 Jul;25(7):1095-9
pubmed: 11443512
Obes Res. 2000 Oct;8(7):516-24
pubmed: 11068957
Am J Clin Nutr. 2000 Sep;72(3):694-701
pubmed: 10966886
Diabetes Metab. 2008 Dec;34(6 Pt 2):649-57
pubmed: 19195626
Diabetol Metab Syndr. 2019 Aug 28;11:74
pubmed: 31467596
Acta Diabetol. 2017 Sep;54(9):805-812
pubmed: 28664417
Hypertension. 2011 Nov;58(5):784-90
pubmed: 21931075
FASEB J. 2002 Jul;16(9):1057-63
pubmed: 12087067
Nutr Metab Cardiovasc Dis. 2010 Sep;20(7):481-90
pubmed: 20659791
Am J Prev Med. 2015 Nov;49(5):661-669
pubmed: 26275960
Eur Endocrinol. 2017 Aug;13(2):86-90
pubmed: 29632614
Obesity (Silver Spring). 2011 Sep;19(9):1796-803
pubmed: 21720429
Obes Rev. 2010 Jan;11(1):11-8
pubmed: 19656312
Jpn Heart J. 2002 Nov;43(6):607-19
pubmed: 12558125
Korean J Fam Med. 2019 Mar;40(2):63-71
pubmed: 30929417
Cell Metab. 2014 Oct 7;20(4):614-25
pubmed: 25242226
Diabetes Obes Metab. 2018 Mar;20(3):734-739
pubmed: 28950422
Clin Nutr ESPEN. 2020 Oct;39:22-29
pubmed: 32859320
Metabolism. 2017 Feb;67:80-89
pubmed: 28081781
Diabetol Metab Syndr. 2014 Mar 31;6(1):47
pubmed: 24684779
Lancet Diabetes Endocrinol. 2021 Sep;9(9):551-552
pubmed: 34358470
Hypertension. 2009 Apr;53(4):577-84
pubmed: 19237685
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2421-32
pubmed: 16973967
Clin Endocrinol (Oxf). 2009 Jun;70(6):876-82
pubmed: 18778397
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
JAMA. 2021 Apr 13;325(14):1414-1425
pubmed: 33755728
J Clin Hypertens (Greenwich). 2018 Jul 1;:
pubmed: 29962012
JAMA. 2014 Jan 1;311(1):74-86
pubmed: 24231879
Front Cardiovasc Med. 2020 May 13;7:88
pubmed: 32478100
JAMA. 2016 Jun 14;315(22):2424-34
pubmed: 27299618
Nutrition. 2003 May;19(5):457-66
pubmed: 12714101
Cureus. 2022 Sep 17;14(9):e29262
pubmed: 36277516
Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725
pubmed: 31301983
Nutrients. 2022 Apr 24;14(9):
pubmed: 35565754
Circulation. 2007 Sep 4;116(10):1170-5
pubmed: 17698735
J Am Coll Cardiol. 2018 May 22;71(20):2360-2372
pubmed: 29773163
Eur Heart J. 2018 Dec 7;39(46):4101-4108
pubmed: 30358832
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Cell Metab. 2018 Mar 6;27(3):588-601.e4
pubmed: 29514067
Nutrients. 2021 Jul 28;13(8):
pubmed: 34444750
Proc Nutr Soc. 2000 Nov;59(4):505-9
pubmed: 11115784
Biomedicines. 2023 May 11;11(5):
pubmed: 37239098
Diabetes Obes Metab. 2023 Aug;25(8):2058-2072
pubmed: 37055715
Br J Clin Pharmacol. 2009 Aug;68(2):201-6
pubmed: 19694739
Br J Radiol. 2012 Jan;85(1009):1-10
pubmed: 21937614
Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):707-713
pubmed: 29744741
J Hypertens. 2014 Jun;32(6):1178-88
pubmed: 24621808
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Circulation. 2011 Dec 13;124(24):e837-41
pubmed: 22156000
Curr Opin Clin Nutr Metab Care. 2015 Nov;18(6):535-51
pubmed: 26335310
Diabetes Obes Metab. 2013 Sep;15(9):863-6
pubmed: 23489381
Pharmaceuticals (Basel). 2023 Jan 30;16(2):
pubmed: 37139804
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
Curr Hypertens Rep. 2018 Jul 10;20(9):77
pubmed: 29992362
Public Health Nutr. 2009 Apr;12(4):497-506
pubmed: 18547457
N Engl J Med. 2021 Sep 2;385(10):896-907
pubmed: 34215025
JAMA. 2021 Apr 13;325(14):1403-1413
pubmed: 33625476
Am J Cardiol. 1998 Feb 26;81(4A):18B-25B
pubmed: 9526809
Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1253-61
pubmed: 16531507
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Diabetes. 2007 Apr;56(4):1010-3
pubmed: 17287468
Circ Res. 2015 Mar 13;116(6):991-1006
pubmed: 25767285
Mol Metab. 2020 Dec;42:101092
pubmed: 33010471
Endocrinology. 2004 May;145(5):2273-82
pubmed: 14726444
Am Heart J. 2020 Nov;229:61-69
pubmed: 32916609
Drug Des Devel Ther. 2011 Apr 05;7:267-78
pubmed: 23630412
Eur Heart J. 2009 Apr;30(7):850-6
pubmed: 19136488